We treated two mGlu1-expressing human melanoma cell lines with Riluzole in combination with Sorafenib in cell proliferation/viability in vitro MTT (methylthiazolyldiphenyl-tetrazolium bromide) assays and in vivo xenograft assays. Here, GRM1 is linked to melanoma.